文献速递乳腺癌

帕妥珠单抗相关腹泻与皮疹和生存结局的关联:CLEOPATRA试验探索性分析

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
PubMed 文献 · Eur J Cancer · 2020-12-31

该研究基于CLEOPATRA试验的808例HER2阳性转移性乳腺癌患者,回顾性分析皮疹和腹泻与PFS及OS的预后及预测价值,采用landmark分析控制永生时间偏倚。结果显示皮疹在两个队列中均为PFS和OS的预后因素,腹泻仅在多西他赛停药后队列中为PFS的预后因素,但两者均不能预测帕妥珠单抗的获益。

要点

  • 皮疹在治疗全程均为PFS和OS的预后因素
  • 腹泻仅在多西他赛停药后为PFS的预后因素
  • 皮疹和腹泻均不能预测帕妥珠单抗的获益

核心结论

  • 在接受帕妥珠单抗、曲妥珠单抗和多西他赛治疗的患者中,皮疹在治疗期间任何时候出现均具有预后价值,而腹泻仅在多西他赛停药后出现时具有预后价值。
  • 皮疹和腹泻均不能预测帕妥珠单抗的获益。

研究设计与样本

  • 本研究为多中心、前瞻性、随机化CLEOPATRA试验的回顾性分析。
  • 共纳入808例HER2阳性转移性乳腺癌患者,采用landmark分析控制永生时间偏倚,定义队列1(C1,从治疗开始)和队列2(C2,多西他赛停药后)。
  • 应用landmark分析后,C1和C2分别纳入777例和518例患者。
  • 研究终点为无进展生存期(PFS)和总生存期(OS),采用单变量和多变量Cox比例风险模型。

主要发现

  • 在C1中,皮疹发生于271例患者(34.9%),腹泻发生于470例患者(60.5%)。
  • 皮疹在C1和C2中均为PFS和OS的预后因素(C1:校正风险比[aHR] = 0.66 [95% CI = 0.48-0.91],p = 0.010;C2:aHR 0.52 [95% CI = 0.30-0.89],p = 0.018)。
  • 腹泻仅在C2中为PFS的预后因素(aHR = 0.65 [95% CI = 0.46-0.91],p = 0.011)。
  • 皮疹和腹泻在两个队列中均不能预测帕妥珠单抗的获益(以PFS/OS衡量)。

临床怎么用

  • 皮疹可作为接受帕妥珠单抗联合曲妥珠单抗和多西他赛治疗的HER2阳性转移性乳腺癌患者的预后标志物。
  • 腹泻仅在多西他赛停药后出现时具有预后价值,临床解读需结合治疗阶段。
  • 皮疹和腹泻不应被用于选择帕妥珠单抗获益人群。

局限性

  • 本研究为回顾性探索性分析,结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skin rash and diarrhoea are known side-effects of pertuzumab. Studies with other anti-HER2 agents suggested that adverse events correlate with patient outcomes. In this exploratory cohort of patients with metastatic HER2-positive breast cancer included in the CLEOPATRA trial we evaluated the value of rash and diarrhoea as prognostic markers and as predictors of pertuzumab benefit. METHODS: This is a retrospective analysis of the multicenter, prospective, randomised CLEOPATRA trial. We defined two analytic cohorts: cohort 1 (C1) included patients from treatment initiation, and cohort 2 (C2) included patients after discontinuation of docetaxel. A landmark analysis was introduced to deal with immortal-time bias. Study endpoints were progression-free survival (PFS) and overall survival (OS). Univariable and multivariable Cox proportional hazards models were used. RESULTS: Of the 808 patients and after application of the landmark analysis, C1 and C2 included 777 and 518 patients, respectively. In C1, rash occurred in 271 patients (34.9%) and diarrhoea in 470 (60.5%). Rash was prognostic for PFS and OS (C1: adjusted hazard ratio [aHR] = 0.66 [95% CI = 0.48-0.91], p = 0.010]; C2: aHR 0.52 [95% CI = 0.30-0.89], p = 0.018) in both cohorts, while diarrhoea was only prognostic for PFS in cohort 2 (aHR = 0.65 [95% CI = 0.46-0.91], p = 0.011). Rash and diarrhoea were not predictive of pertuzumab benefit (in terms of PFS/OS) in the two cohorts. CONCLUSIONS: In patients treated with pertuzumab, trastuzumab, and docetaxel, rash is prognostic whenever it occurs during treatment, while diarrhoea only has prognostic value when occurring after docetaxel discontinuation. However, neither rash nor diarrhoea predict pertuzumab benefit.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. R Ferreira A, Ferreira S, Lambertini M, et al. Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. Eur J Cancer. 2020. PMID: 33388492. doi:10.1016/j.ejca.2020.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。